Clinical Trial Update: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine given with routine pediatric vaccines in healthy US infants…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Quadrivalent meningococcal conjugate vaccine (meningococcal conjugate vaccine quadrivalent (MenACWY))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Healthy Volunteers (Meningococcal Infection) | Phase 3 | Status: COMPLETED | Results posted: 2024-10-15